drugset
drugset / Trial / NCT01979601

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

NCT01979601 ↗

Phase 1 Completed 74 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to measure the effects of LGT209 when given intravenously to patients with high cholesterol who are on stable doses of statin medications, and to healthy subjects with elevated cholesterol

Timeline

Start
2010-12
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject LGT209 Unknown 0.3 mg/kg Intravenous
Subject LGT209 Unknown 1 mg/kg Intravenous
Subject LGT209 Unknown 3 mg/kg Intravenous
Subject LGT209 Unknown 10 mg/kg Intravenous
Subject LGT209 Unknown 20 mg/kg Intravenous

Indications

hyperlipoproteinemia